Associations Between Serum Adipokine, Antipsychotic Exposure, and Clinical Characteristics in Chronic Schizophrenia: A Cross‐Sectional Study
Neuropsychopharmacology Reports · 2026-06 · 46 (2)
DOI: 10.1002/npr2.70123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 22.04.2026. Verfasst von Yasuhiro Ohno und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Showa Medical University Graduate School of Psychiatry, Tokyo, Japan. Hauptthemen laut MEDLINE: Schizophrenia, Antipsychotic Agents, Adiponectin, Adipokines. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Research Foundation for Clinical Pharmacology.
Abstract (Originalsprache)
Background
Previous meta‐analyses have reported lower serum adiponectin levels in patients with schizophrenia treated with second‐generation antipsychotics. However, the relationships among serum adipokines, psychiatric symptoms, and antipsychotic use remain unclear. This study aimed to clarify associations between serum adipokines, psychiatric symptoms, and antipsychotic treatment in patients with chronic schizophrenia compared with healthy controls.
Methods
The study included 37 inpatients with schizophrenia and 39 age‐ and gender‐matched healthy controls. Fasting blood samples were collected, and serum adipokine levels were measured using enzyme‐linked immunosorbent assays. Psychiatric symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS), and antipsychotic doses were converted to chlorpromazine equivalents. Correlations were examined using regression and multivariate analyses, including adjustment for body mass index (BMI).
Results
No significant case–control differences were observed in total or high‐molecular weight adiponectin levels. Female patients had a significantly higher leptin/adiponectin ratio than female controls ( p = 0.041). In the schizophrenia group, adiponectin levels were positively correlated with chlorpromazine equivalents ( r = 0.684, p < 0.001). This association remained statistically significant after adjustment for BMI, gender and hospitalization period. Adiponectin levels were not significantly associated with psychiatric symptom severity.
Conclusion
In this cross‐sectional sample, serum adiponectin levels are associated with antipsychotic dosage but not with symptom severity. These findings suggest that adipokine regulation in patients with schizophrenia may be influenced by treatment‐related and demographic factors. Longitudinal studies incorporating comprehensive metabolic assessments are needed to explore the clinical significance of these relationships.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Showa Medical University Graduate School of Psychiatry, Tokyo, Japan.
- Department of Pharmaceutics, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan.
- Department of Clinical Research and Development School of Pharmacy, Showa Medical University Graduate School of Pharmacy, Tokyo, Japan.
ORCID-Profile: Yasuhiro Ohno
Förderung
- Japan Research Foundation for Clinical Pharmacology
Zitieren
APA
Ohno, Y., Saito, K., Hanabusa, K., Nakai, A., Nagai, T., Hida, N., & Sanada, K. (2026). Associations Between Serum Adipokine, Antipsychotic Exposure, and Clinical Characteristics in Chronic Schizophrenia: A Cross‐Sectional Study. Neuropsychopharmacology Reports, 46(2). https://doi.org/10.1002/npr2.70123
Vancouver
Ohno Y, Saito K, Hanabusa K, Nakai A, Nagai T, Hida N, et al. Associations Between Serum Adipokine, Antipsychotic Exposure, and Clinical Characteristics in Chronic Schizophrenia: A Cross‐Sectional Study. Neuropsychopharmacology Reports. 2026;46(2). doi:10.1002/npr2.70123
BibTeX
@article{Ohno2026,
author = {Ohno, Yasuhiro and Saito, Kiyomi and Hanabusa, Keita and Nakai, Ayaka and Nagai, Tomoko and Hida, Noriko and Sanada, Kenji},
title = {Associations Between Serum Adipokine, Antipsychotic Exposure, and Clinical Characteristics in Chronic Schizophrenia: A Cross‐Sectional Study},
journal = {Neuropsychopharmacology Reports},
year = {2026},
volume = {46},
number = {2},
doi = {10.1002/npr2.70123}
}
EUVIMED